Treatment Guidelines for PTSD: A Systematic Review

Abstract

Background: The aim of this review was to assess the quality of international treatment guidelines for post-traumatic stress disorder (PTSD), and identify differences between guideline recommendations, with a focus on the treatment of nightmares. Methods: Guidelines were identified through electronic searches of MEDLINE, CINAHL, PubMed, Embase and Science Direct, as well as web-based searches of international guideline repositories, websites of psychiatric organisations and targeted web-searches for guidelines from the three most populous English-speaking countries in each continent. Data in relation to recommendations were extracted and the AGREE II criteria were applied to assess for quality. Results: Fourteen guidelines, published between 2004 -2020, were identified for inclusion in this review. Only five were less than 5 years old. Three guidelines scored highly across all AGREE II domains, while others varied between domains. Most guidelines consider both psychological and pharmacological therapies as first-line in PTSD. All but one guideline recommended cognitive behavioural therapy (CBT) as first-line psychological treatment, and selective serotonin reuptake inhibitors (SSRIs) as first-line pharmacological treatment. Most guidelines do not mention the targeted treatment of nightmares as a symptom of PTSD. Prazosin is discussed in several guidelines for the treatment of nightmares, but recommendations vary widely. Most PTSD guidelines were deemed to be of good quality; however, many could be considered out of date. Recommendations for core PTSD symptoms do not differ greatly between guidelines. However, despite the availability of targeted treatments for nightmares, most guidelines do not adequately address this. Conclusions: Guidelines need to be kept current to maintain clinical utility. Improvements are most needed in the AGREE II key domains of ‘applicability’, ‘rigour of development’ and ‘stakeholder involvement’. Due to the treatment-resistant nature of nightmares, guideline development groups should consider producing more detailed recommendations for their targeted treatment. More high-quality trials are also required to provide a solid foundation for making these clinical recommendations for the management of nightmares in PTSD.

Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

“…However, specific therapeutic approaches to manage post-traumatic stress disorder might be needed. 36 With obesity being associated with both non-recovery and severity of long COVID, whether weight reduction using combined pharmacological and non-pharmacological approaches can ameliorate long COVID warrants further investigation. Beyond diet and lifestyle interventions, GLP-1 analogues have been reported to achieve clinically important weight reduction in adults.…”

Voluntary Age Regression Entering “Headspace” in a Child With Post-traumatic Stress Disorder

“…For pharmacotherapy, selective serotonin reuptake inhibitors (SSRIs) are generally regarded as the first-line therapy, specifically for fluoxetine or paroxetine. The serotonin/norepinephrine reuptake inhibitor venlafaxine is also seen as a common recommendation for first-line pharmacotherapy [ 6 ]. A systematic review conducted by Martin et al in 2021 found that one-third of guidelines recommended psychotherapy over pharmacotherapy, and all chose cognitive-behavioral therapy (CBT) as first-line [ 6 ].…”

“…The serotonin/norepinephrine reuptake inhibitor venlafaxine is also seen as a common recommendation for first-line pharmacotherapy [ 6 ]. A systematic review conducted by Martin et al in 2021 found that one-third of guidelines recommended psychotherapy over pharmacotherapy, and all chose cognitive-behavioral therapy (CBT) as first-line [ 6 ]. Our patient was maintained on fluoxetine while inpatient and recommended for trauma-focused CBT outpatient as part of her therapy per these guidelines.…”

Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

“…There are no published RCTs that examined the direct effect of THC or CBD on depressive symptoms [ 155 ]. However, many published RCTs have examined the effects of THC or THC:CBD on other conditions, such as pain and multiple sclerosis (MS) [ 156 ].…”